The anti‐parasitic drug miltefosine suppresses activation of human eosinophils and ameliorates allergic inflammation in mice
Open Access
- 2 February 2021
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (5), 1234-1248
- https://doi.org/10.1111/bph.15368
Abstract
Background and purpose Miltefosine is an alkylphosphocholine drug with proven effectiveness against various types of parasites and cancer cells. Miltefosine is not only able to induce direct parasite killing but also modulates host immunity, for example by reducing the severity of allergies in patients. To date, there are no reports on the effect of miltefosine on eosinophils, central effector cells involved in allergic inflammation. Experimental approach We tested the effect of miltefosine on the activation of human eosinophils and their effector responses in vitro and in mouse models of eosinophilic migration and ovalbumin‐induced allergic lung inflammation. Key results The addition of miltefosine suppressed several eosinophilic effector reactions such as CD11b up‐regulation, degranulation, chemotaxis and downstream signaling. Miltefosine significantly reduced the infiltration of immune cells into the respiratory tract of mice in an allergic cell recruitment model. Finally, in a model of allergic inflammation, treatment with miltefosine resulted in an improvement of lung function parameters. Conclusion and implications Our observations suggest a strong modulatory activity of miltefosine in the regulation of eosinophilic inflammation in vitro and in vivo. Our data underline the potential efficacy of miltefosine in the treatment of allergic diseases and other eosinophil associated disorders and may raise important questions regarding the immunomodulatory effect of miltefosine in patients treated for Leishmania infections.Funding Information
- Austrian Science Fund (P30144, DK‐MOLIN, W1241)
This publication has 68 references indexed in Scilit:
- Randomized, double‐blind, placebo‐controlled study of safety and efficacy of miltefosine in antihistamine‐resistant chronic spontaneous urticariaJournal of the European Academy of Dermatology and Venereology, 2012
- Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisJournal of Antimicrobial Chemotherapy, 2012
- IFN-γ-inducible protein of 10 kDa upregulates the effector functions of eosinophils through β2integrin and CXCR3Respiratory Research, 2011
- EP4 receptor stimulation down-regulates human eosinophil functionCellular and Molecular Life Sciences, 2011
- IgE, mast cells, basophils, and eosinophilsJournal of Allergy and Clinical Immunology, 2010
- Effects of endogenous glucocorticoids on allergic inflammation and TH1/TH2 balance in airway allergic diseaseAnnals of Allergy, Asthma & Immunology, 2009
- Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cellsThe Journal of Experimental Medicine, 2008
- Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapyRetrovirology, 2008
- Miltefosine Affects Lipid Metabolism in Leishmania donovani PromastigotesAntimicrobial Agents and Chemotherapy, 2007
- Hierarchy of eosinophil chemoattractants: role of p38 mitogen-activated protein kinaseEuropean Journal of Immunology, 2006